| Drug Name: | Clindamycin (18323-44-9) |
|---|---|
| PubChem ID: | 53245639 |
| SMILES: | CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl |
| InchiKey: | KDLRVYVGXIQJDK-PSUNAQLJSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Enzyme Inhibitors, Protein Synthesis Inhibitors |
| Molecular Weight (dalton) | : | 424.991 |
| LogP | : | 0.3895 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 102.26 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Gentamicin (1403-66-3) | Nephrotoxicity | Additive | Not known | Renal failure following gentamicin in combination with clindamycin |
| Kaolin (1332-58-7) | Diarrhoea | Antagonistic | It seems probable that the lincomycin becomes adsorbed onto the kaolin, thereby reducing its bioavailability. The kaolin also coats the lining of the gut and acts as a physical barrier to absorption | Pharmacokinetic evaluation of a drug interaction between kaolin--pectin and clindamycin |
| Warfarin (81-81-2) | International Normalized Ratio Increased | Antagonistic | Not understood | Managing patients on warfarin therapy: a case report |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category